Neogenomics Inc (NEO) 4.33 $NEO
N-of-One Selected by NeoGenomics to Provide Clinical Evidence for Interpreting Solid Tumor Next-Generation Sequencing Tests
Business Wire - Tue Dec 02, 7:31AM CST
N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced an agreement with NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services. Under this agreement, N-of-One will provide clinical and interpretive evidence for NeoGenomics solid tumor next-generation sequencing (NGS) tests being used by community pathologists and oncologists. Financial terms of the agreement are not disclosed.
NEO: 4.33 (+0.08)
Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST
FRM: 7.34 (-0.13), NEO: 4.33 (+0.08), AU: 8.21 (-0.06), FNHC: 25.23 (-0.15), AMS: 2.43 (-0.08), NYMX: 0.33 (-0.05), AMDA: 0.69 (-0.01), CVD: 101.94 (-0.71), GBIM: 7.40 (-0.60), RCAP: 11.81 (-0.10), KBIO: 1.80 (-0.10), COOL: 0.67 (-0.01), SAPE: 24.83 (+0.01), XTLB: 2.50 (-0.03), GERN: 3.24 (+0.01), ANIP: 54.28 (+2.33), BBLU: 0.75 (-0.03), NXTD: 2.31 (-0.11), AP: 17.67 (-0.27), ALQA: 4.01 (-0.14)
NeoGenomics' (NEO) CEO Doug VanOort on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 1:31AM CDT
NEO: 4.33 (+0.08)
Neogenomics raises full year 2014 guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 8:51AM CDT
NEO: 4.33 (+0.08)
Neogenomics beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 6:26AM CDT
NEO: 4.33 (+0.08)
NeoGenomics Reports 38% increase in Revenue to a Record $23.2 Million and Adjusted EBITDA of $2.6 Million for the Third Quarter of 2014
PR Newswire - Thu Oct 30, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the third quarter of 2014.
NEO: 4.33 (+0.08)
NeoGenomics to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, October 30, 2014
ACCESSWIRE - Wed Oct 29, 3:13PM CDT
FT. MYERS, FL / ACCESSWIRE / October 29, 2014 / NeoGenomics Inc. (NASDAQ:NEO) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Thursday, October 30, 2014 at 11:00 AM Eastern Time.
NEO: 4.33 (+0.08)
NeoGenomics is First to Offer Molecular Testing for Resistance to Bruton Tyrosin Kinase Inhibitors for Chronic Lymphocytic Leukemia
PR Newswire - Thu Oct 23, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has launched new tests for the detection of mutations in the Bruton tyrosine kinase (BTK) and PLC-gama2 genes for predicting acquired resistance to BTK inhibitors. In addition, NeoGenomics launched a lymphoma profiling test specifically to predict susceptibility to BTK inhibitors and test for mutations in CXCR4, CD79B, MYD88, and CARD11 genes in various types of lymphoma.
NEO: 4.33 (+0.08)
NeoGenomics Launches 315 Gene Next Generation Sequencing Test for Solid Tumor Discovery Profiling
PR Newswire - Thu Oct 16, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the addition of a new comprehensive solid tumor profiling test designed for clinical discovery and to support clinical trials. The test utilizes next generation sequencing ("NGS"
to analyze variants in the coding sequence of 315 genes and uses conventional Fluorescent in Situ Hybridization ("FISH" methods to identify large deletions, amplifications and translocations in 9 different chromosomal loci.
NEO: 4.33 (+0.08)
NeoGenomics Appoints Robert J. Shovlin as Chief Operating Officer
PR Newswire - Mon Sep 29, 4:00PM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the appointment of Robert Shovlin as Chief Operating Officer. This appointment will be effective as of Mr. Shovlin's expected start date of October 13, 2014.
NEO: 4.33 (+0.08)
NeoGenomics Schedules its Q3 2014 Earnings Release for October 30, 2014
PR Newswire - Wed Sep 24, 2:28PM CDT
NeoGenomics, Inc. (NASDAQ: NEO)announced today that it plans to release its third quarter 2014 financial results on Thursday October 30, 2014.
NEO: 4.33 (+0.08)
3 Under-$10 Stocks Triggering Breakout Trades
at The Street - Wed Sep 10, 6:00AM CDT
Keep these stocks under $10 on your trading radar.
NEO: 4.33 (+0.08), DPRX: 11.57 (+0.12), GCAP: 8.26 (-0.06)
5 Under-$10 Stocks Making Big Moves Higher
at The Street - Fri Sep 05, 7:18AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
IRMD: 10.05 (+0.05), MY: 2.13 (+0.03), NEO: 4.33 (+0.08), LINC: 2.80 (-0.11), ARO: 2.31 (+0.09)
5 Breakout Stocks Under $10 Set to Soar
at The Street - Thu Aug 28, 1:39PM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
CAMT: 3.03 (-0.05), AGRX: 5.95 (-0.03), NEO: 4.33 (+0.08), CYTR: 2.29 (+0.05), ATRS: 2.40 (-0.05), TA: 10.37 (+0.21)
NeoGenomics Announces Closing of Recent Equity Offering and Exercise in Full of Underwriters' Over-Allotment Option
PR Newswire - Fri Aug 22, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO) (the "Company" , a leading provider of cancer-focused genetic testing services, today announced that it has closed on the public offering of an additional 1.05 million shares of common stock at an offering price of $4.60 per share as a result of the exercise in full of the underwriters' over-allotment option. The total gross proceeds of the offering, including the exercise in full of the over-allotment option were approximately $37.0 million from the sale of a total of 8.05 million common shares. The net proceeds to the Company, after deducting the underwriters' discount and other estimated expenses will be approximately $34.6 million. The Company plans to use the net proceeds for working capital, capital expenditures and for general corporate purposes including potential acquisitions and the repayment of debt.
NEO: 4.33 (+0.08)
NeoGenomics Announces Pricing of $32.2 Million Public Offering
PR Newswire - Fri Aug 15, 8:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO) (the "Company" , a leading provider of cancer-focused genetic testing services, today announced that it has priced an underwritten public offering of 7.0 million shares of common stock at a price to the public of $4.60 per share. The transaction is expected to close on August 20, 2014 and will result in gross proceeds to NeoGenomics of $32.2 million. The net proceeds to the Company, after deducting the underwriters' discounts and other estimated offering expenses, will be approximately $30.0 million. The Company plans to use the net proceeds for working capital, capital expenditures and for general corporate purposes, including potential acquisitions and the repayment of debt. NeoGenomics has granted the underwriters a 30-day option to purchase up to an additional 1.05 million shares of common stock to cover over-allotments, if any.
NEO: 4.33 (+0.08)
NeoGenomics Announces Public Offering of Common Stock
PR Newswire - Thu Aug 14, 3:01PM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by NeoGenomics.
NEO: 4.33 (+0.08)
Scheduled Conference Calls and Product Launches - Research Reports on Anika Therapeutics, NeoGenomics, HeartWare, Sangamo and Dyax
PR Newswire - Wed Jul 23, 7:40AM CDT
Today, Analysts Review released its research reports regarding Anika Therapeutics, Inc. (NASDAQ: ANIK), NeoGenomics, Inc. (NASDAQ: NEO), HeartWare International Inc (NASDAQ: TWR), Sangamo BioSciences, Inc. (NASDAQ: SGMO) and Dyax Corp (NASDAQ: DYAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5011-100free.
NEO: 4.33 (+0.08), SGMO: 16.53 (+2.46), ANIK: 37.48 (-1.23), HTWR: 70.66 (+0.18), DYAX: 14.18 (-0.05)
Why NeoGenomics, Inc. Stock Rocketed Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Jul 17, 1:01PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of NeoGenomics , a cancer-focused provider of...
NEO: 4.33 (+0.08)
Nasdaq stocks posting largest percentage increases
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
ZIPR: 6.74 (-0.01), FRED: 15.82 (+0.87), NEO: 4.33 (+0.08), SSRI: 5.29 (-0.08), IMGN: 10.01 (unch), DISCB: 35.49 (-0.75), DISCA: 33.38 (-0.67), ASBB: 20.49 (-0.01), INTC: 36.22 (-0.48), JAXB: 12.24 (+0.02), ALXA: 1.35 (-0.10), DISCK: 32.54 (-0.65), SSO.TO: 6.11 (-0.08), AMTX: 4.33 (+0.04), ICAD: 9.13 (-0.15), SCSS: 25.96 (+0.25), TSEM: 13.52 (+0.18), RNWK: 6.90 (+0.02), DGLY: 15.55 (+1.34)
N-of-One Selected by NeoGenomics to Provide Clinical Evidence for Interpreting Solid Tumor Next-Generation Sequencing Tests
Business Wire - Tue Dec 02, 7:31AM CST
N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced an agreement with NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services. Under this agreement, N-of-One will provide clinical and interpretive evidence for NeoGenomics solid tumor next-generation sequencing (NGS) tests being used by community pathologists and oncologists. Financial terms of the agreement are not disclosed.
NEO: 4.33 (+0.08)
Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST
FRM: 7.34 (-0.13), NEO: 4.33 (+0.08), AU: 8.21 (-0.06), FNHC: 25.23 (-0.15), AMS: 2.43 (-0.08), NYMX: 0.33 (-0.05), AMDA: 0.69 (-0.01), CVD: 101.94 (-0.71), GBIM: 7.40 (-0.60), RCAP: 11.81 (-0.10), KBIO: 1.80 (-0.10), COOL: 0.67 (-0.01), SAPE: 24.83 (+0.01), XTLB: 2.50 (-0.03), GERN: 3.24 (+0.01), ANIP: 54.28 (+2.33), BBLU: 0.75 (-0.03), NXTD: 2.31 (-0.11), AP: 17.67 (-0.27), ALQA: 4.01 (-0.14)
NeoGenomics' (NEO) CEO Doug VanOort on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 1:31AM CDT
NEO: 4.33 (+0.08)
Neogenomics raises full year 2014 guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 8:51AM CDT
NEO: 4.33 (+0.08)
Neogenomics beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 6:26AM CDT
NEO: 4.33 (+0.08)
NeoGenomics Reports 38% increase in Revenue to a Record $23.2 Million and Adjusted EBITDA of $2.6 Million for the Third Quarter of 2014
PR Newswire - Thu Oct 30, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the third quarter of 2014.
NEO: 4.33 (+0.08)
NeoGenomics to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, October 30, 2014
ACCESSWIRE - Wed Oct 29, 3:13PM CDT
FT. MYERS, FL / ACCESSWIRE / October 29, 2014 / NeoGenomics Inc. (NASDAQ:NEO) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Thursday, October 30, 2014 at 11:00 AM Eastern Time.
NEO: 4.33 (+0.08)
NeoGenomics is First to Offer Molecular Testing for Resistance to Bruton Tyrosin Kinase Inhibitors for Chronic Lymphocytic Leukemia
PR Newswire - Thu Oct 23, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has launched new tests for the detection of mutations in the Bruton tyrosine kinase (BTK) and PLC-gama2 genes for predicting acquired resistance to BTK inhibitors. In addition, NeoGenomics launched a lymphoma profiling test specifically to predict susceptibility to BTK inhibitors and test for mutations in CXCR4, CD79B, MYD88, and CARD11 genes in various types of lymphoma.
NEO: 4.33 (+0.08)
NeoGenomics Launches 315 Gene Next Generation Sequencing Test for Solid Tumor Discovery Profiling
PR Newswire - Thu Oct 16, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the addition of a new comprehensive solid tumor profiling test designed for clinical discovery and to support clinical trials. The test utilizes next generation sequencing ("NGS"
to analyze variants in the coding sequence of 315 genes and uses conventional Fluorescent in Situ Hybridization ("FISH" methods to identify large deletions, amplifications and translocations in 9 different chromosomal loci. NEO: 4.33 (+0.08)
NeoGenomics Appoints Robert J. Shovlin as Chief Operating Officer
PR Newswire - Mon Sep 29, 4:00PM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the appointment of Robert Shovlin as Chief Operating Officer. This appointment will be effective as of Mr. Shovlin's expected start date of October 13, 2014.
NEO: 4.33 (+0.08)
NeoGenomics Schedules its Q3 2014 Earnings Release for October 30, 2014
PR Newswire - Wed Sep 24, 2:28PM CDT
NeoGenomics, Inc. (NASDAQ: NEO)announced today that it plans to release its third quarter 2014 financial results on Thursday October 30, 2014.
NEO: 4.33 (+0.08)
3 Under-$10 Stocks Triggering Breakout Trades
at The Street - Wed Sep 10, 6:00AM CDT
Keep these stocks under $10 on your trading radar.
NEO: 4.33 (+0.08), DPRX: 11.57 (+0.12), GCAP: 8.26 (-0.06)
5 Under-$10 Stocks Making Big Moves Higher
at The Street - Fri Sep 05, 7:18AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
IRMD: 10.05 (+0.05), MY: 2.13 (+0.03), NEO: 4.33 (+0.08), LINC: 2.80 (-0.11), ARO: 2.31 (+0.09)
5 Breakout Stocks Under $10 Set to Soar
at The Street - Thu Aug 28, 1:39PM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
CAMT: 3.03 (-0.05), AGRX: 5.95 (-0.03), NEO: 4.33 (+0.08), CYTR: 2.29 (+0.05), ATRS: 2.40 (-0.05), TA: 10.37 (+0.21)
NeoGenomics Announces Closing of Recent Equity Offering and Exercise in Full of Underwriters' Over-Allotment Option
PR Newswire - Fri Aug 22, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"
, a leading provider of cancer-focused genetic testing services, today announced that it has closed on the public offering of an additional 1.05 million shares of common stock at an offering price of $4.60 per share as a result of the exercise in full of the underwriters' over-allotment option. The total gross proceeds of the offering, including the exercise in full of the over-allotment option were approximately $37.0 million from the sale of a total of 8.05 million common shares. The net proceeds to the Company, after deducting the underwriters' discount and other estimated expenses will be approximately $34.6 million. The Company plans to use the net proceeds for working capital, capital expenditures and for general corporate purposes including potential acquisitions and the repayment of debt. NEO: 4.33 (+0.08)
NeoGenomics Announces Pricing of $32.2 Million Public Offering
PR Newswire - Fri Aug 15, 8:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"
, a leading provider of cancer-focused genetic testing services, today announced that it has priced an underwritten public offering of 7.0 million shares of common stock at a price to the public of $4.60 per share. The transaction is expected to close on August 20, 2014 and will result in gross proceeds to NeoGenomics of $32.2 million. The net proceeds to the Company, after deducting the underwriters' discounts and other estimated offering expenses, will be approximately $30.0 million. The Company plans to use the net proceeds for working capital, capital expenditures and for general corporate purposes, including potential acquisitions and the repayment of debt. NeoGenomics has granted the underwriters a 30-day option to purchase up to an additional 1.05 million shares of common stock to cover over-allotments, if any. NEO: 4.33 (+0.08)
NeoGenomics Announces Public Offering of Common Stock
PR Newswire - Thu Aug 14, 3:01PM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by NeoGenomics.
NEO: 4.33 (+0.08)
Scheduled Conference Calls and Product Launches - Research Reports on Anika Therapeutics, NeoGenomics, HeartWare, Sangamo and Dyax
PR Newswire - Wed Jul 23, 7:40AM CDT
Today, Analysts Review released its research reports regarding Anika Therapeutics, Inc. (NASDAQ: ANIK), NeoGenomics, Inc. (NASDAQ: NEO), HeartWare International Inc (NASDAQ: TWR), Sangamo BioSciences, Inc. (NASDAQ: SGMO) and Dyax Corp (NASDAQ: DYAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5011-100free.
NEO: 4.33 (+0.08), SGMO: 16.53 (+2.46), ANIK: 37.48 (-1.23), HTWR: 70.66 (+0.18), DYAX: 14.18 (-0.05)
Why NeoGenomics, Inc. Stock Rocketed Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Jul 17, 1:01PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of NeoGenomics , a cancer-focused provider of...
NEO: 4.33 (+0.08)
Nasdaq stocks posting largest percentage increases
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
ZIPR: 6.74 (-0.01), FRED: 15.82 (+0.87), NEO: 4.33 (+0.08), SSRI: 5.29 (-0.08), IMGN: 10.01 (unch), DISCB: 35.49 (-0.75), DISCA: 33.38 (-0.67), ASBB: 20.49 (-0.01), INTC: 36.22 (-0.48), JAXB: 12.24 (+0.02), ALXA: 1.35 (-0.10), DISCK: 32.54 (-0.65), SSO.TO: 6.11 (-0.08), AMTX: 4.33 (+0.04), ICAD: 9.13 (-0.15), SCSS: 25.96 (+0.25), TSEM: 13.52 (+0.18), RNWK: 6.90 (+0.02), DGLY: 15.55 (+1.34)
